Other types of cellular therapy have also been explored with encouraging results of an ongoing trial with natural killer (NK) cells derived from umbilical cord blood (CB) and activated with a novel bispecific antibody known as AFM13 (targeting CD16A and CD30) demonstrated safety and efficacy in r/r CD30+ lymphoma (NCT04074746) (125). Here, TNFRSF8 is linked to lymphoma.